These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25370722)

  • 1. Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients.
    Bolkun L; Lemancewicz D; Piszcz J; Moniuszko M; Bolkun-Skornicka U; Szkiladz M; Jablonska E; Kloczko J; Dzieciol J
    Hematol Oncol; 2015 Dec; 33(4):199-205. PubMed ID: 25370722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.
    Bolkun L; Lemancewicz D; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
    Ann Hematol; 2014 Apr; 93(4):635-44. PubMed ID: 24141333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.
    Secchiero P; Gonelli A; Carnevale E; Corallini F; Rizzardi C; Zacchigna S; Melato M; Zauli G
    Neoplasia; 2004; 6(4):364-73. PubMed ID: 15256058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions.
    Na HJ; Hwang JY; Lee KS; Choi YK; Choe J; Kim JY; Moon HE; Kim KW; Koh GY; Lee H; Jeoung D; Won MH; Ha KS; Kwon YG; Kim YM
    Angiogenesis; 2014 Jan; 17(1):179-94. PubMed ID: 24097299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.
    Gazitt Y; Shaughnessy P; Montgomery W
    Cytokine; 1999 Dec; 11(12):1010-9. PubMed ID: 10623426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.
    Lemancewicz D; Bolkun L; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
    Leuk Res; 2013 Sep; 37(9):1089-93. PubMed ID: 23768867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
    Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
    Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic markers in plasma cell myeloma patients treated with novel agents.
    Medinger M; Halter J; Heim D; Buser A; Gerull S; Stern M; Passweg J
    Anticancer Res; 2015 Feb; 35(2):1085-90. PubMed ID: 25667497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.
    Coulon S; Francque S; Colle I; Verrijken A; Blomme B; Heindryckx F; De Munter S; Prawitt J; Caron S; Staels B; Van Vlierberghe H; Van Gaal L; Geerts A
    Cytokine; 2012 Aug; 59(2):442-9. PubMed ID: 22658783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.
    Bolkun L; Lemancewicz D; Sobolewski K; Mantur M; Semeniuk J; Kulczynska A; Kloczko J; Dzieciol J
    Adv Med Sci; 2013; 58(1):118-25. PubMed ID: 23333895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
    Pal S; Shankar BS; Sainis KB
    Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.